An observational study in Lung Cancer, sponsored by AstraZeneca. Completed at 29 sites in France. Open to participants aged Up to 130 Years. Per ClinicalTrials.gov, last updated 2016-07-04.
Sponsored by AstraZeneca · Observational
The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life
Descriptive pharmacoepidemiological study of patients treated with Iressa
7,334 studies on the registry are indexed under Lung Neoplasms; 1,554 are open to participants now.
This study's enrollment of 361 is above the median of 190 across 1,547 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →AstraZeneca is the lead sponsor of 3,492 studies on the registry; 265 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 176 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Hospital, clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Overall survival
Time frame: 24 months
The progression free survival
Time frame: 24 months
Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC)
Time frame: baseline
Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC)
Time frame: From baseline to 3 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 3 months to 6 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 6 months to 12 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 12 months to 18 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 18 months to 24 months
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.